Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) shares dropped 1.7% during trading on Monday . The company traded as low as $10.70 and last traded at $11.24. Approximately 1,354,564 shares traded hands during trading, an increase of 301% from the average daily volume of 337,931 shares. The stock had previously closed at $11.43.
Silverback Therapeutics Stock Performance
The stock has a market cap of $405.29 million, a PE ratio of -4.64 and a beta of 0.60. The business has a 50-day moving average of $12.85 and a 200 day moving average of $12.66.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Read More
- Five stocks we like better than Silverback Therapeutics
- How to Plot Fibonacci Price Inflection Levels
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- The Basics of Support and Resistance
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
